Sign up for Table of Contents Alerts.
Email this page
Print this page
Report
Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: A possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition
Marianne S. Poruchynsky, Dan L. Sackett, Robert W. Robey, Yvona Ward, Christina Annunziata and Tito Fojo
volume 7 | issue 7
1 April 2008Pages: 940 - 949
Subscribe to this journal for $129/year
Bortezomib (VelcadeŽ), a proteasome inhibitor, is approved by the FDA for the treatment of multiple myeloma (MM). While effective, its use has been hampered by peripheral neurotoxicity of unexplained etiology. Since proteasome inhibitors alter protein degradation, we speculated that proteins regulating microtubule (MT) stability may be affected after treatment and examined MT polymerization in cells by comparing the distribution of tubulin between polymerized (P) and soluble (S) fractions. We observed increased MT polymerization following treatment of SY5Y and KCNR [neuroblastoma], HCN2, and 8226 [MM] cells, using five proteasome inhibitors; the baseline proportion of total α-tubulin in ‘P’ fractions ranged from ~41-68%, and increased to ~55-99% after treatment. Increased acetylated α-tubulin, a post-translational marker of stabilized MTs, was observed in the neural cell lines HCN1A and HCN2 and this was sustained up to 144 hours after the proteasome inhibitor was removed. Cell cycle analysis of three cell lines after treatment, showed ~50-75% increases in the G2M phase. Immunofluorescent localization studies of proteasome inhibitor treated cells did not reveal microtubule bundles in contrast to paclitaxel treated, suggesting MT stabilization via a mechanism other than direct drug binding. We examined the levels of microtubule associated proteins and observed a 1.4-3.7 fold increase in the microtubule associated protein MAP2, in HCN2 cells following treatment with proteasome inhibitors. These data provide a plausible explanation for the neurotoxicity observed clinically and raise the possibility that microtubule stabilization contributes to cytotoxicity.
Authors
Marianne S. Poruchynsky
National Cancer Institute; Bethesda, MD
Dan L. Sackett
National Institute of Child Health and Human Development; Bethesda, MD
Robert W. Robey
National Cancer Institute; Bethesda, MD
Yvona Ward
National Cancer Institute; Bethesda, MD
Christina Annunziata
National Cancer Institute; Bethesda, MD
Tito Fojo
National Cancer Institute; Bethesda, MD